All In Biotech

Drug Trial Radar · NCT03066947

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Last checked: Nov 20, 2026Latest source record: Jan 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 5, 2017

Primary completion

Nov 22, 2018

Study completion Nov 22, 2018

Sponsor

Sponsor type
Industry
Collaborators
Cancer Insight, LLC
First posted
Mar 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation \~2 and \~4 days after the inoculation. These is repeated every 2 weeks for one month (3 treatments), then monthly for up to one year. Standard tumor assessments are performed at baseline and then every 2-3 months.

Conditions

  • Breastcancer
  • Breast Neoplasm

Interventions

  • SV-BR-1-GMBiological

    See above

  • CyclophosphamideDrug

    Low dose pre-treatment to reduce regulatory T cells

  • Interferon-alpha-2bBiological

    Low dose given in the vaccine site to boost the immune response

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety]Time frame: Through study completion, an average of 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • University of Miami/Sylvester at Plantation

    Plantation, Florida

  • Cancer Center of Kansas (CCK)

    Wichita, Kansas

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Providence Regional Medical Center

    Everett, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.